The therapy demonstrated good tolerability across all assessed cohorts, with no reports of serious or severe treatment-emergent adverse events. Credit: PeopleImages / Shutterstock.com. SCYNEXIS has ...
While Lilly and Eisai/Biogen validated the amyloid theory in Alzheimer's disease, there are several trials of drugs with ...
Metsera said the Phase III trial should be initiated by the end of 2025. Image credit: Alones / Shutterstock.com. Pfizer’s $4.9bn bet on obesity startup Metsera is looking promising, with 14.1% weight ...
The intensity of TEAEs observed in the subjects during the treatment period was predominantly mild to moderate. Credit: Image Point Fr / Shutterstock.com. China Medical System and its subsidiary ...
ACL Digital will also be able to drive digital transformation for biotech, pharmaceutical and medical device companies. Credit: tilialucida / Shutterstock.com. ACL Digital has acquired US-based ...
On 24 September, uniQure announced positive topline results from its pivotal Phase I/II studies (HD-GENE-TRX1, HD-GENE-TRX2) ...
Though Eli Lilly has shelved the obesity and T2D trial involving Zepbound, the US pharma will continue its obesity-only trial ...
PepGen’s stock has risen by over 120% after its investigational myotonic DM1 candidate reported the highest mean splicing ...
Anebulo prioritised developing selonabant IV formulation as a potential treatment for paediatric patients with acute cannabis toxicity. Credit: murat photographer / Shutterstock.com. Anebulo ...
Bayer vice president Luiz Barberini explains how the German giant’s cooperation with suppliers fosters long-term trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback